Abstract
Chronic Obstructive Pulmonary Disease (COPD), being a major cause of morbidity and mortality worldwide, is a major problem for public health. It is predicted that its burden will continuously expand over the next years. This article is an up-to-date review of both non-pharmacologic and pharmacologic management of COPD, which is now based on new staging systems, able to predict prognosis and the response to different treatment approaches. Non-pharmacologic therapies, such as smoking cessation, vaccinations and pulmonary rehabilitation are covered briefly. Current pharmacologic management covers short acting beta-agonists (SABA), short acting muscarinic antagonists (SAMA), long acting beta agonists (LABA), long acting antimuscarinics (LAMA), inhaled corticosteroids (ICS), LABA/ICS combinations, xanthines, specific phosphodiesterase 4 (PDE4) inhibitors and oxygen therapy.
Keywords: Chronic obstructive pulmonary disease (COPD), disease management, pharmacotherapy, phenotypes, rehabilitation.
Current Respiratory Medicine Reviews
Title:Management of Stable COPD: An Update
Volume: 9 Issue: 6
Author(s): Alexandru Corlateanu, Gloria Montanari, Alexandros G. Mathioudakis, Victor Botnaru and Nikolaos Siafakas
Affiliation:
Keywords: Chronic obstructive pulmonary disease (COPD), disease management, pharmacotherapy, phenotypes, rehabilitation.
Abstract: Chronic Obstructive Pulmonary Disease (COPD), being a major cause of morbidity and mortality worldwide, is a major problem for public health. It is predicted that its burden will continuously expand over the next years. This article is an up-to-date review of both non-pharmacologic and pharmacologic management of COPD, which is now based on new staging systems, able to predict prognosis and the response to different treatment approaches. Non-pharmacologic therapies, such as smoking cessation, vaccinations and pulmonary rehabilitation are covered briefly. Current pharmacologic management covers short acting beta-agonists (SABA), short acting muscarinic antagonists (SAMA), long acting beta agonists (LABA), long acting antimuscarinics (LAMA), inhaled corticosteroids (ICS), LABA/ICS combinations, xanthines, specific phosphodiesterase 4 (PDE4) inhibitors and oxygen therapy.
Export Options
About this article
Cite this article as:
Corlateanu Alexandru, Montanari Gloria, G. Mathioudakis Alexandros, Botnaru Victor and Siafakas Nikolaos, Management of Stable COPD: An Update, Current Respiratory Medicine Reviews 2013; 9 (6) . https://dx.doi.org/10.2174/1573398X10666140222001646
DOI https://dx.doi.org/10.2174/1573398X10666140222001646 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The First Case Report of Kabuki Syndrome from the National Iranian Registry of Primary Immunodeficiencies
Endocrine, Metabolic & Immune Disorders - Drug Targets Are we Genomic Mosaics? Variations of the Genome of Somatic Cells can Contribute to Diversify our Phenotypes
Current Genomics L-Arginine Transport in Disease
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Role of Glycogen Synthase Kinase-3 in Insulin Resistance and Type 2 Diabetes
Current Drug Targets Current and Future Applications for Stem Cell Therapies in Spine Surgery
Current Stem Cell Research & Therapy The Development of Stem Cell-Based Treatment for Liver Failure
Current Stem Cell Research & Therapy Immune Therapy for Infectious Diseases at the Dawn of the 21st Century: the Past, Present and Future Role of Antibody Therapy, Therapeutic Vaccination and Biological Response Modifiers
Current Pharmaceutical Design AICD Nuclear Signaling and Its Possible Contribution to Alzheimers Disease
Current Alzheimer Research Aging and Remodeling During Healing of the Wounded Heart: Current Therapies and Novel Drug Targets
Current Drug Targets New Insights into Invasive Aspergillosis - from the Pathogen to the Disease
Current Pharmaceutical Design Advanced Glycation: A Novel Outlook on Atherosclerosis
Current Pharmaceutical Design Recent Trends in Analytical Methods to Determine New Psychoactive Substances in Hair
Current Neuropharmacology Functional Link Between Adenosine and Insulin: A Hypothesis for Fetoplacental Vascular Endothelial Dysfunction in Gestational Diabetes
Current Vascular Pharmacology T Cell Tuning for Tumour Therapy: Enhancing Effector Function and Memory Potential of Therapeutic T cells
Current Gene Therapy Overcoming Drug Resistance by Enhancing Apoptosis of Tumor Cells
Current Cancer Drug Targets Agomelatine in the Treatment of Major Depressive Disorder: An Assessment of Benefits and Risks
Current Neuropharmacology Mimetics of the Peptide β-Strand
Mini-Reviews in Medicinal Chemistry Dry Eye Disease: Present Challenges in the Management and Future Trends
Current Pharmaceutical Design Interaction Between Platelets and Cytokines - A Possible Role in the Pathogenesis of Preeclampsia
Vascular Disease Prevention (Discontinued) Intestinal Absorption Enhancement Via the Paracellular Route by Fatty Acids, Chitosans and Others: A Target for Drug Delivery
Current Drug Delivery